****

**Target Grants – Brief synopsis**

**Submit your synopsis to amfar (**[**GRANTS@AMFAR.org**](mailto:amfar@grants.org)**)**

**usE the subject line: [your last name], [your first name] – target grant synopsis**

**Your (PI) name \_\_\_; degree(s) \_\_\_; Institution: \_\_\_**

**Working project title: \_\_\_**

**Describe the clinical intervention you’re working towards:**

* Intervention/product (i.e., pill(s), vaccine(s), etc.; dosing schedule/timing; target population; other important details): (1-2 sentences) \_\_\_
* efficacy goal (primary endpoint): e.g., 6-month delay to virologic rebound, etc. The goal should be clinical (i.e., experienced by the participant), not assay-based. \_\_\_
* Other important outcome measures: (may be assay-based) \_\_\_

**Provide information on the existing data supporting your idea:**

|  |  |  |
| --- | --- | --- |
| **Category of data** | **Available? Yes/No**  **(provide a response on every row)** | **Link(s) to reference(s)**  **(provide links for every yes)** |
| In vitro safety |  |  |
| Ex vivo safety |  |  |
| Animal safety |  |  |
| Clinical safety |  |  |
| In vitro efficacy |  |  |
| Ex vivo efficacy |  |  |
| Animal efficacy |  |  |
| Clinical efficacy |  |  |

**Your plan**:

Which model system? (ex vivo, animal or clinical) \_\_\_

Which does your goal pertain to - safety or efficacy?: \_\_\_

The cut-off, expressed quantitatively, at which the intervention/product would be deemed successful and worthy of further study (e.g., how many log drop in viral load, specific relative change in breadth or amplitude of specific immune response, etc.): \_\_\_

Total cost (including up to 20% indirect costs): $\_\_\_

Performance period: **\_\_\_1 year \_\_\_2 years**

**Plan narrative** (250 words or less): \_\_\_

**If successful, what research project comes next** (250 words or less): \_\_\_